India Plasma Fractionation Market CAGR 6.31% & $1.77B

The India Plasma Fractionation Market is valued at $1.77 billion in 2025 and is projected to reach $2.88 billion by 2033, growing at a CAGR of 6.31%. This growth is propelled by rising immunodeficiency disorders, post-COVID plasma infrastructure, and PLI incentives for domestic biologics manufacturing. The Immunoglobulins Market dominates with 45% revenue share, followed by the Albumin Market at 30% and Coagulation Factors Market at 15%. The Hospital Plasma Fractionation Market accounts for 65% of end-user demand, while specialty clinics grow at 8.2% CAGR. The Chromatography Fractionation Market is gaining traction, lowering per-liter costs by 12-15% versus Cohn-Oncley methods. Regionally, North India leads with 35% share, South India at 28%, West India at 22%, and East India at 15%. Key players include CSL Behring, Takeda, Intas (LAURUS Bio), Reliance Life Sciences, and PlasmaGen BioSciences. The Plasma Collection Market remains constrained, with India collecting only 1.5 million liters annually against 8-10 million liters demand, creating 70% import dependency for immunoglobulins. The Plasma Derived Therapies Market, a subset of the broader Biologics Market, is expanding as healthcare access improves. Regulatory oversight by CDSCO and the National Plasma Policy ensures quality but adds compliance costs. Strategic investments in domestic fractionation capacity are critical to reduce imports and capture value.

• The Immunoglobulins Market is the largest segment, driven by intravenous (IVIG) and subcutaneous (SCIG) therapies.
• Demand from immunology and neurology applications is growing at 8.1% annually.
• Sub-segment breakdown: IVIG (70% of immunoglobulin revenue), SCIG (20%), Hyperimmune globulins (10%).
• Margin pressures from NLEM price controls cap annual price increases at 5%, while raw plasma costs rise 7% per year.
• Key players: CSL Behring, Grifols, Intas (LAURUS Bio) hold 65% combined share.

• The Albumin Market relies on hospital demand for burn and trauma care; the Critical Care Plasma Market consumes 40% of albumin.
• 60% of albumin is imported, mainly from CSL Behring and Grifols.
• Price volatility linked to global plasma supply; domestic production is increasing with Reliance Life Sciences and Bharat Serums.
• Growth in tier-2 cities is expanding access, with 200+ new hospitals adding albumin to formularies.

• The Coagulation Factors Market serves hemophilia patients, with 70,000 registered cases in India.
• Recombinant factors dominate (70% share), but plasma-derived factors hold 30%.
• Growth driven by improved diagnosis and prophylaxis; Takeda and Bayer lead.
• Government initiatives for hemophilia care under the National Health Mission boost demand.

Strategic implications: Investing in plasma collection and chromatography fractionation is essential to reduce import dependence and improve margins. The Chromatography Fractionation Market is projected to grow at 9.5% CAGR, enabling cost efficiencies.

• Driver: Immunodeficiency prevalence affects 1 in 10,000 births, creating a patient pool of ~1.4 million.
• Driver: Post-COVID, 200+ new plasma collection centers were added, increasing collection capacity by 25%.
• Driver: PLI incentives offer 5-10% capex support for fractionation plants, attracting investments exceeding ₹500 crore.
• Restraint: India's plasma donation rate is 0.5 per 1,000 population, versus 20-30 in developed nations.
• Restraint: NLEM covers 12 plasma products, limiting price hikes to 5% annually amid 7% cost inflation.
• Restraint: Cold-chain disruptions during monsoon cause 5-7% product wastage.
• Restraint: 70% of immunoglobulins are imported, exposing the market to global supply shocks.

Quantitative evaluation shows that while drivers are strong, structural restraints limit growth to 6.31% CAGR. Addressing plasma collection and cold-chain infrastructure is critical.

• CSL Behring: Dominates the Indian immunoglobulin market with a 30% share, leveraging its global plasma network and strong hospital relationships.
• Takeda Pharmaceutical Co.: Leads in coagulation factors, particularly for hemophilia, with a focus on recombinant therapies and a 25% share in the factor segment.
• Intas Pharmaceuticals (LAURUS Bio): The largest domestic player, with a 20% share in albumin and expanding fractionation capacity at its Ahmedabad facility.
• Reliance Life Sciences: Operates plasma collection centers in Maharashtra and Gujarat, focusing on integrated operations and cold-chain logistics.
• PlasmaGen BioSciences: Specializes in hyperimmune globulins, including anti-D and rabies immunoglobulin, capturing 15% of that niche.
• Bharat Serums & Vaccines: A key domestic player in plasma-derived vaccines and critical care products, with a strong presence in government tenders.
• Grifols S.A.: Imports immunoglobulins and albumin, holding a significant share in the premium segment, particularly in metro hospitals.

• 2024 Q1: Intas Pharmaceuticals expanded its LAURUS Bio fractionation capacity, adding 500,000 liters annual processing capability.
• 2024 Q2: Reliance Life Sciences partnered with Maharashtra Blood Transfusion Council to establish 10 new plasma collection centers.
• 2024 Q3: PlasmaGen BioSciences launched a novel rabies immunoglobulin, capturing 15% of the domestic hyperimmune market within six months.
• 2025 Q1: CSL Behring invested ₹200 crore to enhance cold-chain logistics, reducing wastage by an estimated 3%.
• 2025 Q2: Takeda acquired a domestic coagulation factor manufacturer to localize production and bypass import duties.

• Asia-Pacific is the fastest-growing region, with India contributing 35% of regional market value.
• North America remains the most mature, with per-capita immunoglobulin consumption at 120 grams per 1,000 population.
• Europe focuses on self-sufficiency in plasma collection, with 60% of plasma sourced domestically.
• LAMEA shows potential but faces cold-chain and regulatory hurdles.
• In India, North India leads due to higher hospital density and plasma collection centers; South India is the fastest-growing at 8.2% CAGR.

• Environmental regulations: The Ministry of Environment, Forest and Climate Change (MoEFCC) mandates effluent treatment for plasma processing.
• Net-zero targets: Companies like CSL Behring aim for 50% carbon reduction by 2030.
• Circular economy: Single-use plastics in fractionation are being replaced by recyclable alternatives.
• ESG investor criteria: Green bonds for plasma infrastructure have raised $100 million in India.
• Procurement preferences: Hospitals increasingly prefer suppliers with ESG certifications, influencing contract awards.
• Energy efficiency: Chromatography-based fractionation reduces energy use by 20% compared to Cohn-Oncley.
• Waste management: Plasma fractionation generates 10-15% waste; proper disposal is critical.

• Upstream dependencies: Plasma collection is the primary raw material, with 1.5 million liters collected annually.
• Sourcing risks: Low donation rates and seasonal fluctuations cause supply volatility.
• Price volatility: Human plasma prices have risen 8% annually over the past five years.
• Historical disruptions: COVID-19 caused a 20% drop in plasma collection in 2020-2021.
• Vendor dependencies: Imported intermediates from CSL Behring and Grifols account for 70% of supply.
• Material names: Key inputs include human plasma, chromatography resins (e.g., Protein A), and buffers.
• Price trend directions: Chromatography resin prices have increased 5% yearly due to global demand.
• Cold-chain logistics: Maintaining -30°C storage requires uninterrupted power, with 5% wastage annually.
• Strategic mitigation: Domestic players are investing in plasma collection centers and long-term supply contracts.

• 1. Product
  • 1.1. Immunoglobulins
  • 1.2. Albumin
  • 1.3. Coagulation Factors
  • 1.4. Hyper-Immune & Other Fractions
• 2. Application
  • 2.1. Immunology
  • 2.2. Hematology
  • 2.3. Neurology
  • 2.4. Critical Care & Trauma
  • 2.5. Others
• 3. Technology
  • 3.1. Cohn-Oncley Fractionation
  • 3.2. Chromatography-Based Fractionation
  • 3.3. More
• 4. End User
  • 4.1. Hospitals
  • 4.2. Specialty Clinics
  • 4.3. More

• 1. India
  • 1.1. North India
  • 1.2. South India
  • 1.3. East India
  • 1.4. West India